- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Atai Life Sciences, a Peter Thiel-backed company that produces psychedelic and non-psychedelic mushroom-based therapies for depression and anxiety, is expected to go public. We'll update this page as new information emerges.
Our top picks for where to buy ATAI Life Sciences BV stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy ATAI Life Sciences stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ATAI. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy ATAI Life Sciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
ATAI Life Sciences stock price (NASDAQ: ATAI)
Use our graph to track the performance of ATAI stocks over time.ATAI Life Sciences shares at a glance
Information last updated 2024-10-25.
| Latest market close | $1.14 |
|---|---|
| 52-week range | $1.03 - $2.85 |
| 50-day moving average | $1.21 |
| 200-day moving average | $1.60 |
| Wall St. target price | $11.60 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.36 |
Is it a good time to buy ATAI Life Sciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ATAI Life Sciences price performance over time
Historical closes compared with the close of $1.22 from 2024-10-28
| 1 week (2024-10-22) | -4.69% |
|---|---|
| 1 month (2024-09-30) | 5.17% |
| 3 months (2024-07-30) | -19.74% |
| 6 months (2024-04-30) | -38.38% |
| 1 year (2023-10-30) | 2.52% |
|---|---|
| 2 years (2022-10-27) | -59.20% |
| 3 years (2021-10-29) | 14.59 |
| 5 years (2019-10-26) | N/A |
ATAI Life Sciences financials
| Revenue TTM | $378,000 |
|---|---|
| Gross profit TTM | $233,000 |
| Return on assets TTM | -27.97% |
| Return on equity TTM | -31.51% |
| Profit margin | 0% |
| Book value | $1.00 |
| Market Capitalization | $203 million |
TTM: trailing 12 months
ATAI Life Sciences share dividends
We're not expecting ATAI Life Sciences to pay a dividend over the next 12 months.
You may also wish to consider:
ATAI Life Sciences share price volatility
Over the last 12 months, ATAI Life Sciences's shares have ranged in value from as little as $1.025 up to $2.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ATAI Life Sciences's is 0.781. This would suggest that ATAI Life Sciences's shares are less volatile than average (for this exchange).
To put ATAI Life Sciences's beta into context you can compare it against those of similar companies.
- Intellia Therapeutics (NTLA.US): 1.759
- Moderna (MRNA.US): 1.661
ATAI Life Sciences overview
Atai Life Sciences N. V. , a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression.
Frequently asked questions
nullWhat percentage of ATAI Life Sciences is owned by insiders or institutions?
Currently 9.987% of ATAI Life Sciences shares are held by insiders and 27.098% by institutions. How many people work for ATAI Life Sciences?
Latest data suggests 83 work at ATAI Life Sciences. When does the fiscal year end for ATAI Life Sciences?
ATAI Life Sciences's fiscal year ends in December. Where is ATAI Life Sciences based?
ATAI Life Sciences's address is: Wallstrasse 16, Berlin, Germany, 10179 What is ATAI Life Sciences's ISIN number?
ATAI Life Sciences's international securities identification number is: NL0015000DX5
More resources on Finder
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
Ask a question